Acute pancreatitis associated with lamivudine therapy for chronic B hepatitis by TUON, Felipe Francisco et al.
www.bjid.com.br
BJID 2008; 12 (August) 263
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Hyperamylasemia is a common complication during lamivudine use. We report a case of a pancreatitis following
lamivudine therapy. A careful monitoring of amylase levels during treatment with lamivudine is discussed, mainly
in the first weeks, considering the cost of this exam and further complication.
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Side effects associated with lamivudine therapy are
rarely described. Gastrointestinal symptoms, such as
nausea, vomiting, diarrhea, and abdominal pain have
been described, though more severe conditions can
occur, such as rhabdomyolysis and severe anemia [1].
Hyperamylasemia is a well-known complication after
lamivudine use, and serum concentrations of amylase
after 6 to 12 months of treatment are higher than those
before treatment [2]. These side effects are most
commonly described in patients with HIV infection than
in those with chronic B hepatitis. We report a case of
pancreatitis following three weeks of lamivudine therapy,
without severe complications. A complication of
lamivudine treatment in a patient with chronic B hepatitis
is extremely rare, and physicians do not normally
associate lamivudine with side effects.
A 59-year-old man with a history of five years of
chronic B hepatitis (Anti-HBe and HBsAg positive)
initiated treatment with 150 mg lamivudine on February
2007.  This  drug was indicated because
anatomopathological findings showed intense periportal
inf lammation (grade 4)  and increased a lanine
aminotransferase (ALT) levels (195 U/L). The patient was
asymptomatic, so other exams were made: Hb – 15.6 g/
dL; leukocytes – 6,590/mm3; platelets – 164,000/mm3;
prothrombin time – 13,5 seconds (INR – 1.1); aspartate
aminotransferases (AST) – 100U/L; total bilirubin – 0.8
mg/dL; total protein – 7.6 g/dL (albumin – 4.8g/dL); serum
protein electrophoresis showed 23.4% gamma globulines
(1.8g/dL). Renal function was normal.
Fifteen days after beginning on lamivudine, the
patient was admitted to the hospital with intense
abdominal pain, nausea and vomiting, anorexia and
malaise. Serum exams revealed hyperamylasemia (778 U/
L), increased lactate dehydrogenase (233 U/L, normal =
190U/L). Leukocytosis (14,200/mm3) was also found. An
abdominal echography was normal, and computed
tomography revealed a discrete peripancreatic edema,
without  s igns  of  necrosis .  After  f ive  days  of
observational treatment and drug interruption the patient
had a good evolution, with normalization of laboratorial
findings and absence of symptoms.
Lamivudine is an oral nucleoside analog that inhibits
HBV replication and markedly normalizes alanine
transaminase levels. This effect is directly associated
with improvement in liver inflammation and necrosis
activity. As side effects are rarely described, laboratory
monitoring of markers, such as amylase, is not common.
A previous study demonstrated that lamivudine can be
associated with hyperamylasemia, but this increase was
not associated with abdominal pain [3]. We have
demonstrated here that hyperamylasemia can also
involve abdominal pain and other clinical signs/
symptoms of pancreatitis, including discrete imaging
abnormalities. In earlier and larger studies, abdominal
discomfort was not different from what was found in the
placebo group, and no acute pancreatitis was described
[4]. There are only two previous publications indicating
that lamivudine induces pancreatitis [2,5]. We conclude
that amylase elevation can be found in patients with chronic
B hepatitis being treated with lamivudine; however, this
elevation is not always benign. We also suggest careful
monitoring of amylase levels during treatment with
lamivudine, mainly in the first weeks, taking into account
the cost of this exam and of further complications.
References
1. Adani G.L., Baccarani U., Risaliti A., et al. Rhabdomyolysis due to
Lamivudine administration in a liver transplant recipient. Am J
Transplant 2005;5:634.
2. Chen C.H., Changchien C.S., Lu S.N., et al. Lamivudine treatment
for recurrent pancreatitis associated with reactivation of chronic
B hepatitis. Dig Dis Sci 2002;47:564-7.
3. Ertekin V., Selimoglu M.A., Orbak Z. Effects of lamivudine therapy
on the glucose metabolism in children with chronic hepatitis B:
first year follow-up results. Eur J Gastroenterol Hepatol
2005;17:655-9.
4. Dienstag J.L., Schiff E.R., Wright T.L., et al. Lamivudine as initial
treatment for chronic hepatitis B in the United States. N Engl
J Med 1999;341:1256-63.
5. Soylu A.R., Dokmeci G., Tezel A., et al. Lamivudine-induced
acute pancreatitis in a patient with decompensated Hbv-
related chronic l iver disease.  J  Clin Gastroenterol
2004;38:134.
